Trends in burden of multidrug-resistant tuberculosis in countries, regions, and worldwide from 1990 to 2017: results from the Global Burden of Disease study
- PMID: 33676581
- PMCID: PMC7936417
- DOI: 10.1186/s40249-021-00803-w
Trends in burden of multidrug-resistant tuberculosis in countries, regions, and worldwide from 1990 to 2017: results from the Global Burden of Disease study
Abstract
Background: Antituberculosis-drug resistance is an important public health issue, and its epidemiological patterns has dramatically changed in recent decades. This study aimed to estimate the trends of multidrug-resistant tuberculosis (MDR-TB), which can be used to inform health strategies.
Methods: Data were collected from the Global Burden of Disease study 2017. The estimated annual percentage changes (EAPCs) were calculated to assess the trends of MDR-TB burden at global, regional, and national level from 1990 to 2017 using the linear regression model.
Results: Globally, the age-standardized rate (ASR) of MDR-TB burden including incidence, prevalence, death and disability-adjusted life years (DALYs) had pronounced increasing trends from 1990 to 1999, with the EAPCs were 17.63 [95% confidence interval (CI): 10.77-24.92], 17.57 (95% CI 11.51-23.95), 21.21 (95% CI 15.96-26.69), and 21.90 (95% CI 16.55-27.50), respectively. Particularly, the largest increasing trends were seen in areas and countries with low and low-middle sociodemographic index (SDI). However, the trends in incidence, prevalence, death and DALYs of MDR-TB decreased globally from 2000 to 2017, with the respective EAPCs were - 1.37 (95% CI - 1.62 to - 1.12), - 1.32 (95% CI - 1.38 to - 1.26), - 3.30 (95% CI - 3.56 to - 3.04) and - 3.32 (95% CI - 3.59 to - 3.06). Decreasing trends of MDR-TB were observed in most regions and countries, particularly that of death and DALYs in Slovenia were - 18.96 (95% CI - 20.82 to - 17.06) and -19.35 (95% CI - 21.10 to - 17.55), respectively. Whereas the pronounced increasing trends of MDR-TB occurred in Papua New Guinea, Singapore, and Australia.
Conclusions: The ASR of MDR-TB showed pronounced decreasing trends from 2000 to 2017. However, the MDR-TB burden remains a substantial challenge to the TB control globally, and requires effective control strategies and healthcare systems.
Keywords: Age-standardized rate; Epidemiological trend; Estimated annual percentage change; Global burden of disease; Multidrug-resistant tuberculosis.
Conflict of interest statement
The authors declare no competing interests.
Figures





Similar articles
-
Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019.BMC Infect Dis. 2024 Feb 22;24(1):243. doi: 10.1186/s12879-024-09079-5. BMC Infect Dis. 2024. PMID: 38388352 Free PMC article.
-
Global burden of rheumatic heart disease: trends from 1990 to 2019.Arthritis Res Ther. 2022 Jun 11;24(1):138. doi: 10.1186/s13075-022-02829-3. Arthritis Res Ther. 2022. PMID: 35690787 Free PMC article.
-
Global Burden of Tuberculosis in Adolescents and Young Adults: 1990-2019.Pediatrics. 2024 Apr 1;153(4):e2023063910. doi: 10.1542/peds.2023-063910. Pediatrics. 2024. PMID: 38482587
-
Multidrug resistant tuberculosis: trends and control.Indian J Chest Dis Allied Sci. 2014 Oct-Dec;56(4):237-46. Indian J Chest Dis Allied Sci. 2014. PMID: 25962197 Review.
-
The global situation of MDR-TB.Tuberculosis (Edinb). 2003;83(1-3):44-51. doi: 10.1016/s1472-9792(02)00058-6. Tuberculosis (Edinb). 2003. PMID: 12758188 Review.
Cited by
-
Global burden of multidrug-resistant tuberculosis in children and adolescents.Pediatr Res. 2025 Feb 11. doi: 10.1038/s41390-025-03917-1. Online ahead of print. Pediatr Res. 2025. PMID: 39934644
-
Rifampicin resistant Mycobacterium tuberculosis and associated factors among presumptive pulmonary tuberculosis patients in Mogadishu, Somalia.SAGE Open Med. 2023 Jan 10;11:20503121221148603. doi: 10.1177/20503121221148603. eCollection 2023. SAGE Open Med. 2023. PMID: 36643204 Free PMC article.
-
Characterization of Genetic Mutations in Multi-Drug-Resistant Isolates of Mycobacterium tuberculosis Bacilli Conferring Resistance to a Second-Line Anti-tuberculosis Drug.Cureus. 2023 Jun 14;15(6):e40442. doi: 10.7759/cureus.40442. eCollection 2023 Jun. Cureus. 2023. PMID: 37456413 Free PMC article.
-
Discovery of novel and potent InhA direct inhibitors by ensemble docking-based virtual screening and biological assays.J Comput Aided Mol Des. 2023 Dec;37(12):695-706. doi: 10.1007/s10822-023-00530-4. Epub 2023 Aug 29. J Comput Aided Mol Des. 2023. PMID: 37642861
-
Global burden of HIV-negative multidrug- and extensively drug-resistant tuberculosis based on Global Burden of Disease Study 2021.Sci One Health. 2024 Jul 4;3:100072. doi: 10.1016/j.soh.2024.100072. eCollection 2024. Sci One Health. 2024. PMID: 39763639 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical